Skip to main content

Incyte to Present at Upcoming Investor Conferences

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September:

  • Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 at 12:45 pm (EDT)



  • Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6, 2024 at 10:45 am (EDT)



  • Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 9:45 am (EDT)

The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

About Incyte

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  240.80
-3.39 (-1.39%)
AAPL  289.24
-1.31 (-0.45%)
AMD  470.56
-4.95 (-1.04%)
BAC  54.64
+0.22 (0.41%)
GOOG  362.36
+0.07 (0.02%)
META  581.77
-2.82 (-0.48%)
MSFT  402.35
-1.06 (-0.26%)
NVDA  205.59
-2.60 (-1.25%)
ORCL  208.32
+2.51 (1.22%)
TSLA  386.77
-9.91 (-2.50%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.